Compare VanEck Junior Gold Miners (GDXJ) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
VanEck Junior Gold Miners vs ResMed Inc. — how do they compare? VanEck Junior Gold Miners trades at $114.32 (market cap $8.22B), while ResMed Inc. trades at $230.12 (market cap $31.89B). The key difference: ResMed Inc. is far larger — about 3.9× VanEck Junior Gold Miners's market cap, and ResMed Inc. pays a 1.16% dividend while VanEck Junior Gold Miners pays none. Which is the better fit depends on your goals — on Pluang, investors hold VanEck Junior Gold Miners for 41 Days and ResMed Inc. for 51 Days on average.
| GDXJ | RMD | |
|---|---|---|
Market Cap | $8.22B | $31.89B |
Volume | 3,212,198 | 618,314 |
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $156.19 | $277.88 |
52-Week Low | $87.56 | $182.82 |
Typical Hold Time | 41 Days | 51 Days |
Enterprise Value | — | $31.24B |
Dividend Yield | — | 1.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GDXJ, the VanEck Junior Gold Miners ETF, trades at $114.39, up 4.81% in the last 24 hours. The technical outlook is bearish, with moving averages and key indicators like ADX signaling selling pressure. Recent news highlights multiple junior gold mining companies being added to the ETF's underlying index, potentially increasing its diversification and appeal. However, key financial ratios such as P/E and P/S are unavailable for direct analysis of the ETF's valuation.
The outlook for GDXJ is mixed, balancing recent index additions against a bearish technical backdrop. Investment opportunities lie in exposure to junior gold miners amid high gold prices, but risks include sector volatility and the ETF's current negative momentum. Investors should weigh the potential for broader market recognition against prevailing selling pressure.
ResMed (RMD) trades at $230.91, up 2.18% today, with a bullish technical signal and strong fundamentals. The company reported consistent earnings beats in recent quarters, with Q3 2026 EPS expected at $2.68. Revenue grew to $5.15B in 2025, with a net income margin of 26.94%. Analyst consensus is a buy, with a $242.70 price target. Recent news highlights EPS growth targets of 12%-14% and participation in investor conferences.
Outlook is positive due to robust earnings growth and market share gains, but risks include competitive pressures and regulatory investigations. The stock offers upside to the consensus target, supported by institutional buying and solid cash flow generation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About VanEck Junior Gold Miners
GDXJ provides exposure to small and mid-cap companies in the global gold and silver mining industry. It focuses on 'junior' miners involved in exploration and early production, featuring 2026 leaders like Pan American Silver and Coeur Mining.
Read more on GDXJ →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
